Literature DB >> 22274538

Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses.

Slava Stamova1, Anja Feldmann, Marc Cartellieri, Claudia Arndt, Stefanie Koristka, Falko Apel, Rebekka Wehner, Marc Schmitz, Martin Bornhäuser, Malte von Bonin, Gerhard Ehninger, Holger Bartsch, Michael Bachmann.   

Abstract

There is growing interest in the development of novel single-chain bispecific antibodies for retargeting of immune effector T cells to tumor cells. Until today, functional fusion constructs consisting of a single-chain bispecific antibody and a fluorescent protein were not reported. Such molecules could be useful for an in vivo visualization of this retargeting process. Recently, we established two novel single-chain bispecific antibodies. One is capable of retargeting T cells to CD33, and the other is capable of retargeting T cells to the prostate stem cell antigen (PSCA). CD33 is an attractive immunotarget on the surface of tumor cells from patients with acute myeloid leukemia (AML). The PSCA is a potential target on prostate cancer cells. Flanking the reading frame encoding the green fluorescent protein (GFP) with a recently described novel helical linker element allowed us to establish novel single-chain bispecific fusion antibodies. These fluorescent fusion antibodies were useful to efficiently retarget T cells to the respective tumor cells and visualize the formation of immune synapses between effector and target cells. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22274538     DOI: 10.1016/j.ab.2011.12.042

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  14 in total

1.  Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system.

Authors:  C Arndt; A Feldmann; M von Bonin; M Cartellieri; E-M Ewen; S Koristka; I Michalk; S Stamova; N Berndt; A Gocht; M Bornhäuser; G Ehninger; M Schmitz; M Bachmann
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

2.  Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site.

Authors:  Thomas List; Dario Neri
Journal:  MAbs       Date:  2012-10-02       Impact factor: 5.857

Review 3.  Engineered stem cells targeting multiple cell surface receptors in tumors.

Authors:  Sanam L Kavari; Khalid Shah
Journal:  Stem Cells       Date:  2019-08-21       Impact factor: 6.277

4.  Protein-Antibody Conjugates (PACs): A Plug-and-Play Strategy for Covalent Conjugation and Targeted Intracellular Delivery of Pristine Proteins.

Authors:  Bin Liu; Khushboo Singh; Shuai Gong; Mine Canakci; Barbara A Osborne; S Thayumanavan
Journal:  Angew Chem Int Ed Engl       Date:  2021-05-05       Impact factor: 16.823

5.  Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8.

Authors:  Irene Michalk; Anja Feldmann; Stefanie Koristka; Claudia Arndt; Marc Cartellieri; Armin Ehninger; Gerhard Ehninger; Michael P Bachmann
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

6.  Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".

Authors:  Anja Feldmann; Claudia Arndt; Ralf Bergmann; Simon Loff; Marc Cartellieri; Dominik Bachmann; Roberta Aliperta; Mirjam Hetzenecker; Florian Ludwig; Susann Albert; Pauline Ziller-Walter; Alexandra Kegler; Stefanie Koristka; Sebastian Gärtner; Marc Schmitz; Armin Ehninger; Gerhard Ehninger; Jens Pietzsch; Jörg Steinbach; Michael Bachmann
Journal:  Oncotarget       Date:  2017-05-09

Review 7.  Acute myeloid leukemia targets for bispecific antibodies.

Authors:  S S Hoseini; N K Cheung
Journal:  Blood Cancer J       Date:  2017-02-03       Impact factor: 11.037

Review 8.  Redirecting T cells to hematological malignancies with bispecific antibodies.

Authors:  Mireya Paulina Velasquez; Challice L Bonifant; Stephen Gottschalk
Journal:  Blood       Date:  2017-11-08       Impact factor: 25.476

9.  Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.

Authors:  Dongmei Fan; Wei Li; Yuqi Yang; Xiaolong Zhang; Qing Zhang; Yan Yan; Ming Yang; Jianxiang Wang; Dongsheng Xiong
Journal:  J Hematol Oncol       Date:  2015-10-06       Impact factor: 17.388

10.  Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.

Authors:  R Aliperta; M Cartellieri; A Feldmann; C Arndt; S Koristka; I Michalk; M von Bonin; A Ehninger; J Bachmann; G Ehninger; M Bornhäuser; M P Bachmann
Journal:  Blood Cancer J       Date:  2015-09-18       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.